Therapeutic revision of alprazolam;Revisión terapéutica del alprazolam

Ciencia y Tecnologia Pharmaceutica

Volumn 12, Issue 3, 2002, Pages 137-152

  Perez Lozano P ^a   Garcia Montoya E ^a   Orriols Reig, A ^a   Minarro Carmona M ^a   Tico Grau J R ^a   Sune Negre J M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Alprazolam; Pharmacokinetics; Pharmacology; Physical and chemical properties

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CIMETIDINE; CISAPRIDE; CLONAZEPAM; DIAZEPAM; DIGOXIN; DISULERGINE; FLUNITRAZEPAM; FLUOXETINE; FLURAZEPAM; IMIPRAMINE; LITHIUM CARBONATE; LORAZEPAM; NEFAZODONE; NITRAZEPAM; OXAZEPAM; TEMAZEPAM; VALPROIC ACID;

AGGRESSION; AGITATION; AGRANULOCYTOSIS; ANEMIA; ANTEROGRADE AMNESIA; ANTICONVULSANT ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTISOCIAL BEHAVIOR; ANXIETY DISORDER; ATAXIA; AUDITORY HALLUCINATION; BRADYCARDIA; CLINICAL TRIAL; CONCENTRATION LOSS; CONFUSION; DELIRIUM; DEPERSONALIZATION; DEPRESSION; DERMATITIS; DIARRHEA; DIPLOPIA; DISORIENTATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG STABILITY; DRUG STRUCTURE; DYSARTHRIA; DYSPHORIA; EOSINOPHILIA; EPIGASTRIC PAIN; EXCITABILITY; EXTRAVERSION; HEADACHE; HEARING DISORDER; HEART PALPITATION; HEPATITIS; HUMAN; HYPERSALIVATION; HYPERTENSION; HYPERURICOSURIA; HYPOMANIA; HYPOTENSION; INSOMNIA; JAUNDICE; LEUKOPENIA; LIBIDO DISORDER; LUNG DISEASE; MANIA; MASS SPECTROMETRY; MUSCLE SPASM; NAUSEA; NERVOUSNESS; NOSE CONGESTION; NYSTAGMUS; PANIC; PHOTOPHOBIA; PRURITUS; PSYCHOSIS; RESPIRATION DEPRESSION; REVIEW; SEDATION; SOMNOLENCE; STRUCTURE ANALYSIS; TACHYCARDIA; THROMBOCYTOPENIA; TRANQUILIZING ACTIVITY; TREATMENT INDICATION; TREMOR; URINE INCONTINENCE; URTICARIA; VERTIGO; VISUAL DISORDER; VISUAL HALLUCINATION; VISUAL IMPAIRMENT; VOMITING; WITHDRAWAL SYNDROME;

EID: 0036759849     PISSN: 11315253     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Dawson GW, Jue SG, Brogden RN: Alprazolam. A rewiew of its pharmacodynamic properties and efficency in the treatment of anxiety and depression. Drugs. 1984; 27: 132-147.
2. a Edición. Ed Masson. Barcelona, 1997: 383-397.
3. a Ed. Editions du Vidal. París, 2000: 1638-1640.
4. AHFS 2001 Drugs information®. American Society of Health System. Pharmacists, Inc. Bethesda, 2001: 2319-2320.
5. Catálogo de Especialidades Farmacéuticas Consejo General de Colegios Oficiales de Farmacéuticos. Madrid, 2001: 1807-1810.
6. Loc. Cit. 5: 1810-1812.
7. Keller MB, Lavori PW: Influence of depresion on the treatment of panic disorder with imipramine, alprazolam and placebo. J Affective Disorders, 1993; 28 (1): 27-38.
8. Greenblatt DJ, Vonn Moltka LL: Alprazolam, pharmacokinetics, metabolism and plasma levels: Clinical implications. J Clin Psych, 1993; 54 suppl: 4-11; discussion: 12-14.
9. Von Moltka LL, Greenblatt DJ: Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver microsomes. Pharmacology, 1993; 47 (4): 268-276.
10. Garzane PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokin, 1987; 16 (6): 337-364.
11. Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam: Therapeutic implications. Clin Pharmacokin, 1993; 24 (6): 453-471.
12. Joern WA, Joern AB: Detection of alprazolam (Xanax) and its metabolites in urine using dual capillary column, dual nitrogen detector gas cromatography. J Analyt Toxicol, 1987; 11 (6): 247-251.
13. Glassman, Alexander H: Method of Preventing Withdrawal Symptoms Associated with the Cessation or Reduction of Tobacco Smoking. PA 4683231.
14. Golwyn, Daniel H: Treatment of Immunologically Based Disorders, Sepecifically Psoriasis. PA 5147872.
15. Diquet B, Gujadhiu L: Lack of interaction between disulfiram and alprazolam in alcoholic patients. Eur J Clin Psychopharmacol, 1995; 15 (5): 306-319.
16. Kroboth PD, Falan MM: Coadministrtion of nefazodone and benzodiazepines: I. Pharmacodynamic assesment J Clin Pharmacol, 1990; 38 (2): 157-160.
17. a Ed. The Royal Pharmaceutical Press. Londres, 1986: 331.
18. a Ed. Ed Merck & Co. Inc. Rahway. New York, 2001: 57-58.
19. a Ed. Ministerio de Sanidad y Consumo. Madrid, suplemento 2000: 1913-1915
20. a Ed. Strasbourg, 1997: 377-379.
21. USP 24, NF 19. United States Pharmacopeia: Convention; Inc. Rockville, 2000: 64-65.
22. a ed. Orion Corporation Fermion. Manufacturer of Pharmaceuticals and Fine Chemicals. Finlandia, 1997.
23. Mino R. Caira, Barrat Easter: Structure and thermal stability of alprazolam and selected solvates. J Pharm Sci, 1995; 84 (11): 1379-1384